New drug tested to slow kidney damage in rare genetic disease
NCT ID NCT06425055
Summary
This study tested whether a drug called vonafexor is safe and can help protect kidney function in people with Alport syndrome, a genetic condition that damages the kidneys over time. It involved 26 patients who were at risk of their disease getting worse. Participants took the drug for 24 weeks while researchers checked for side effects and measured changes in key kidney health markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dr Anjay Rastogi - UCLA Health, David Geffen School of Medicine
Los Angeles, California, 90095, United States
-
Dr Ankit Mehta - Renal Disease Research Institute
Dallas, Texas, 75126, United States
-
Dr Arnold Silva - Boise Kidney & Hypertension
Boise, Idaho, 83703, United States
-
Dr Eric Wallace - University of Alabama
Birmingham, Alabama, 35294, United States
-
Dr James Simon - Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Dr Moglie Le Quintrec - Hopital Lapeyronie
Montpellier, 34090, France
-
Dr Suneel Udani - NANI Research
Hinsdale, Illinois, 60521, United States
-
Dr Tingting Li - Washington University
St Louis, Missouri, 63110, United States
-
Fundacio Puigvert
Barcelona, 08025, Spain
-
Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Virgen de la Arrixaca
El Palmar, 30120, Spain
-
Pr Claire Rigothier - CHU De Bordeaux
Bordeaux, 33076, France
-
Pr. Bertrand Knebelmann - Necker Enfants Malades
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.